Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Cisplatin vs Paclitaxel in TNBC Evaluating HRD
NCT01982448Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2014
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin in triple-negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started Apr 2014; status: completed.
02
Drugs
cisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01982448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982448.